Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors (original) (raw)

Abstract

Phototoxic lesions generated in tumor tissue by photodynamic therapy (PDT) are recognized by the host as a threat to the integrity and homeostasis at the affected site. Among the canonical pathways invoked by the host for dealing with this type of challenge is the activation of the complement system, integrating proteins that serve as molecular sensors of danger signals produced by PDT and those initiating signalling cascades coupled into the network of inflammatory and immune responses. Since the activated complement system is a salient participant of the antitumor response produced by PDT, it is worth exploring whether its manipulation can be exploited for the therapeutic benefit. Using mouse tumor models, the present study examined the potential of representative complement-activating agents to act as effective adjuvants to PDT. Tumor-localized treatment with zymosan, an alternative complement pathway activator, reduced the recurrence-rate of PDT-treated tumors, markedly increasing the percentage of permanent cures. In contrast, a similar treatment with heat aggregated gamma globulin (complement activator via the classical pathway) was of no significant benefit as a PDT adjuvant. Systemic complement activation with streptokinase treatment had no detectable effect on complement deposition at the tumor site without PDT, but it augmented the extent of complement activity in PDT-treated tumors. This finding based on immunohistochemistry analysis explains the results of tumor therapy experiments, which showed that systemic treatment with streptokinase or a similar agent, urokinase, enhances the PDT-mediated tumor response. Zymosan and streptokinase administrations produced no beneficial results with PDT of tumors growing in complement-deficient mice. This study, therefore, establishes the potential of complement-activating agents to serve as effective adjuvants to PDT for cancer treatment.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan and Q., Peng, Photodynamic Therapy J. Natl. Cancer Inst. 1998 90 889–905
    Article CAS Google Scholar
  2. I. Cecic, B. Stott, J. Sun and M. Korbelik, Relevance of innate immunity recognition of altered self in the induction of host response associated with photodynamic therapy, in Recent Research Development in Cancer, ed. S. G. Pandalai, Transworld Research Network, Trivandrum, India, vol. 5, in press
  3. M. Korbelik and I., Cecic, Mechanism of tumor destruction by photodynamic therapy, in Handbook of Photochemistry and Photobiology, ed. H. S. Nalwa, American Scientific Publishers, Stevenson Ranch, CA, vol. 4, 2003, pp. 39-77
  4. N. R. Cooper, Biology of the complement system, in Inflammation: Basic Principles and Clinical Correlations, ed. J. I. Galin and R. Snyderman, Lippincott Williams & Wilkins, Philadelphia, PA, 1999, pp. 281-315
    Google Scholar
  5. K. Elward and P., Gasque, “Eat me” and “don’t eat me” signals govern the innate immune response and tissue repair in the CNS; emphasis on the critical role of the complement system Mol. Immunol. 2003 40 85–94
    Article CAS Google Scholar
  6. I. Cecic and M., Korbelik, Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors Cancer Lett. 2002 183 43–51
    Article CAS Google Scholar
  7. L. Clemenza, F. Dieli, M. Cicardi and A., Salerno, Research on complement: old issues revisited and a novel sphere of influence Trends Immunol. 2003 24 292–295
    Article Google Scholar
  8. Y. Y. Maeda and G., Chihara, The effects of neonatal thymectomy on the antitumor activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune rsponses Int. J. Cancer 1973 11 153–161
    Article CAS Google Scholar
  9. P. D., Cooper, Solid phase activators of the alternative pathway of complement and their use in vivo, in Activators and Inhibitors of Complement, ed. R. B. Sim, Kluwer Academic Publishers, Amsterdam, 1993, pp. 69-106
    Google Scholar
  10. W. T. Bradner, D. A. Clarke and C. C., Stock, Stimulation of host defense against experimental cancer. I. Zymosan and sarcoma 180 in mice Cancer Res. 1958 18 347–351
    CAS PubMed Google Scholar
  11. T. J. H. Volman, R. J. A. Goris, M. van der Jagt, F. A. J. van de Loo and T., Hendriks, Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase Crit. Care Med. 2002 30 1553–1559
    Article CAS Google Scholar
  12. S. Oren, I. Maslovsky, M. Schlesinger and L., Resin, Complement activation in patients with acute myocardial infarction treated with streptokinase Am. J. Med. Sci. 1998 315 24–29
    CAS PubMed Google Scholar
  13. G. A. Ewald and P. R., Eisenberg, Plasmin-mediated activation of contact system in response to pharmacological thrombolysis Circulation 1995 91 28–36
    Article CAS Google Scholar
  14. M. Korbelik and G., Krosl, Photofrin accumulation in malignant and host cell populations of various tumours Br. J. Cancer 1996 73 506–513
    Article CAS Google Scholar
  15. J. Sun, I. Cecic, C. S. Parkins and M., Korbelik, Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors Photochem. Photobiol. Sci. 2002 1 690–695
    Article CAS Google Scholar
  16. Y. S. Taktak and B., Stenning, Solid pahse enzyme immunoassay for the quantification of serum amyloid P (SAP) and complement component 3 (C3) proteins in acute-phase mouse sera Horm. Metab. Res. 1992 24 371–374
    Article CAS Google Scholar
  17. M. I. Gyongyossy and S. N., Assimeth, Isolation of the third component of mouse complement J. Immunol. 1977 118 1032–1035
    CAS PubMed Google Scholar
  18. H.-P. T. Ekre, B. Fjellner and Ö. Hägermark Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions Int. J. Immunopharmacol. 1986 8 277–286
    Article CAS Google Scholar
  19. L. D. Shultz, P. A. Schwietzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennant, S. McKenna, L. Mobraaten, T. V. Rajan, D. L. Greiner and E. H., Leiter, Multiple defects in innate and adaptive immunological function in NOD/Ltz-scid mice J. Immunol. 1995 154 180–191
    CAS PubMed Google Scholar
  20. W. T. Schaiff and P. R., Eisenberg, Direct induction of complement activation by pharmacologic activation of plasminogen Coron. Artery Dis. 1997 8 9–18
    Article CAS Google Scholar
  21. I. Cecic, C. S. Parkins and M., Korbelik, Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors Photochem. Photobiol. 2001 74 712–720
    Article CAS Google Scholar
  22. I. Cecic and M. Korbelik, unpublished

Download references

Author information

Authors and Affiliations

  1. British Columbia Cancer Agency, Vancouver, B.C., Canada
    Mladen Korbelik, Jinghai Sun & Ivana Cecic
  2. Canadian Blood Services, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, B.C., Canada
    Katherine Serrano

Authors

  1. Mladen Korbelik
    You can also search for this author inPubMed Google Scholar
  2. Jinghai Sun
    You can also search for this author inPubMed Google Scholar
  3. Ivana Cecic
    You can also search for this author inPubMed Google Scholar
  4. Katherine Serrano
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toMladen Korbelik.

Rights and permissions

About this article

Cite this article

Korbelik, M., Sun, J., Cecic, I. et al. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors.Photochem Photobiol Sci 3, 812–816 (2004). https://doi.org/10.1039/b315663J

Download citation